Evaluation of efficacy and safety of generic tacrolimus (Suprotac®) compared to reference tacrolimus (Prograf®) in kidney transplantation: a phase IV study

Submitted: 5 October 2024
Accepted: 29 October 2024
Published: 21 January 2025
Abstract Views: 254
PDF: 123
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Background

Transplant recipients are given an immunosuppressive regimen such as tacrolimus to prevent organ rejection. Suprotac® is a generic tacrolimus that is utilized in kidney transplantation regimen in Iran. This post-market study was conducted to evaluate the safety and efficacy of Suprotac® in comparison with Prograf®.

Methods:

In this two-armed, open-label, parallel, active-controlled, and cohort study, de novo kidney transplant recipients aging 18 to 65 years were prescribed Suprotac® or Prograf® as part of the immunosuppressant protocol. The primary outcome was comparing the mean estimated glomerular filtration rate (eGFR) at month 12. The secondary outcomes were the assessment of patient and graft survival, acute rejections during hospitalization, tacrolimus dose, trough concentration, and trough concentration/dose (C/D) ratio, and adverse events (AEs) during the study period.

Results:

A total of 201 patients were enrolled in this study. At discharge, the eGFR was lower in the Suprotac® group compared to the Prograf® group (51.70 ml/min/1.73m2 and 57.48 ml/min/1.73m2, respectively; p = 0.042). However, at month 12, there was no significant difference in mean eGFR between the two groups (58.94 ml/min/1.73m2 and 59.78 ml/min/1.73m2, respectively; p = 0.772). Other outcomes, including patient and graft survival, acute rejection during hospitalization, tacrolimus dose, trough concentration, and C/D ratio, and overall incidence of AEs were similar between the two groups (p > 0.05).

Conclusion:

The efficacy and safety profile of the generic tacrolimus were shown to be comparable to the reference tacrolimus at month 12.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Kaballo MA, Canney M, O’Kelly P, et al. A comparative analysis of survival of patients on dialysis and after kidney transplantation. Clin Kidney J 2018;11:389-93. DOI: https://doi.org/10.1093/ckj/sfx117
Malekshahi A, MortezaNejad HF, Taromsari MR, et al. An evaluation of the current status of kidney transplant in terms of the type of receipt among Iranian patients. Renal Replacement Ther 2020;6:1-5. DOI: https://doi.org/10.1186/s41100-020-00314-8
Saidi RF, Broumand B. Current challenges of kidney transplantation in Iran: moving beyond the “Iranian Model”. Transplantation 2018;102:1195-7. DOI: https://doi.org/10.1097/TP.0000000000002212
Enderby C, Keller CA. An overview of immunosuppression in solid organ transplantation. Am J Manag Care 2015;21:s12-23.
Duncan MD, Wilkes DS. Transplant-related immunosuppression: a review of immunosuppression and pulmonary infections. Proc Am Thor Soc 2005;2:449-55. DOI: https://doi.org/10.1513/pats.200507-073JS
Lee H, Myoung H, Kim SM. Review of two immunosuppressants: tacrolimus and cyclosporine. J Korean Assoc Oral Maxillofac Surgeons 2023;49:311. DOI: https://doi.org/10.5125/jkaoms.2023.49.6.311
Services USDOHAH. Common Terminology Criteria for Adverse Events (CTCAE) 2017 Version 5.0 [updated November 27, 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.
Use ICoHoTRfRoPfH. maintenance of the ICH guideline on clinical safety data management: Data elements for transmission of individual case safety reports E2B(R2), 2001 [updated 5 February 2001. Available from: https://admin.ich.org/sites/default/files/inline-files/E2B_R2_Guideline.pdf
Centre UM. The use of the WHO-UMC system for standardised case causality assessment 2018 [updated 4 June 2018]. Available from: https://who-umc.org/media/164200/who-umc-causality-assessment_new-logo.pdf
Glotz D, Charpentier B, Abramovicz D, et al. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation 2010;89:1511-7. DOI: https://doi.org/10.1097/TP.0b013e3181db09e4
Marcén R, Morales JM, Fernández-Rodriguez A, et al. Long-term graft function changes in kidney transplant recipients. NDT Plus 2010;3:ii2-ii8. DOI: https://doi.org/10.1093/ndtplus/sfq063
Connor A, Prowse A, Newell P, Rowe PA. A single-centre comparison of the clinical outcomes at 6 months of renal transplant recipients administered Adoport® or Prograf® preparations of tacrolimus. Clin Kidney J 2013;6:21-8. DOI: https://doi.org/10.1093/ckj/sfs154
Poggio ED, Augustine JJ, Arrigain S, et al. Long-term kidney transplant graft survival—Making progress when most needed. Am J Transplant 2021;21:2824-32. DOI: https://doi.org/10.1111/ajt.16463
Ghelichi-Ghojogh M, Ghaem H, Mohammadizadeh F, et al. Graft and patient survival rates in kidney transplantation, and their associated factors: a systematic review and meta-analysis. Iranian J Public Health 2021;50:1555. DOI: https://doi.org/10.18502/ijph.v50i8.6801
Lee HS, Kang M, Kim B, Park Y. Outcomes of kidney transplantation over a 16-year period in Korea: An analysis of the National Health Information Database. Plos One 2021;16:e0247449. DOI: https://doi.org/10.1371/journal.pone.0247449
Schütte-Nütgen K, Thölking G, Steinke J, et al. Fast Tac Metabolizers at Risk ⁻ It is Time for a C/D Ratio Calculation. J Clin Med 2019;8:587. Erratum in: J Clin Med 2019;8:E1870. DOI: https://doi.org/10.3390/jcm8111870
von Samson-Himmelstjerna FA, Messtorff ML, Kakavand N, et al. The tacrolimus concentration/dose ratio does not predict early complications after kidney transplantation. Transpl Internat 2023;36:11027. DOI: https://doi.org/10.3389/ti.2023.11027
Hagh EJ, Mousavi A, Hejazian SM, et al. The impact of single nucleotide polymorphisms on the pharmacokinetics of tacrolimus in kidney allograft recipients of northern-west, Iran. Adv Pharmaceut Bull 2023;13:393. DOI: https://doi.org/10.34172/apb.2023.038
Dashti-Khavidaki S, Ghaffari S, Gohari M, et al. Tacrolimus dose requirement in iranian kidney transplant recipients within the first three weeks after transplantation. Int J Organ Transplantation Med 2016;7:167.
de Jonge H, Vanhove T, de Loor H, et al. Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. Br J Clin Pharmacol 2015;80:548-559 DOI: https://doi.org/10.1111/bcp.12703
Alghanem SS, Soliman MM, Alibrahim AA, et al. Monitoring tacrolimus trough concentrations during the first year after kidney transplantation: a national retrospective cohort study. Frontiers Pharmacol 2020;11:566638. DOI: https://doi.org/10.3389/fphar.2020.566638
Nowicka M, Górska M, Nowicka Z, et al. Tacrolimus: Influence of the posttransplant concentration/dose ratio on kidney graft function in a two-year follow-up. Kidney Blood Pressure Res 2019;44:1075-88. DOI: https://doi.org/10.1159/000502290
Del Bello A, Gaible C, Longlune N, et al. Tacrolimus intrapatient variability after switching from immediate or prolonged-release to extended-release formulation, after an organ transplantation. Front Pharmacol 2021;12:602764. DOI: https://doi.org/10.3389/fphar.2021.602764
Kim H, Han A, Ahn S, et al. Association of high intra-patient variability in tacrolimus exposure with calcineurin inhibitor nephrotoxicity in kidney transplantation. Sci Reports 2023;13:16502. DOI: https://doi.org/10.1038/s41598-023-43755-x
Kim S, Huh K, Han D-J, et al. A 6-month, multicenter, single-arm pilot study to evaluate the efficacy and safety of generic tacrolimus (TacroBell) after primary renal transplantation. Transplantation proceedings; 2009: Elsevier. DOI: https://doi.org/10.1016/j.transproceed.2009.03.061
Pérez-Flores I, Sánchez-Fructuoso A, Calvo N, et al. Incidence and risk factors for the metabolic syndrome and posttransplant diabetes in renal transplant recipients taking tacrolimus. Transplantation proceedings; 2010: Elsevier. DOI: https://doi.org/10.1016/j.transproceed.2010.08.005
Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transpl 2004;4:583-95. DOI: https://doi.org/10.1046/j.1600-6143.2003.00372.x
Jacob D, Marrón B, Ehrlich J, Rutherford PA. Pharmacovigilance as a tool for safety and monitoring: a review of general issues and the specific challenges with end-stage renal failure patients. Drug Healthc Patient Saf 2013;5:105-112. DOI: https://doi.org/10.2147/DHPS.S43104
Alomar M, Tawfiq AM, Hassan N, Palaian S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Therapeutic Adv Drug Safety 2020;11:2042098620938595. DOI: https://doi.org/10.1177/2042098620938595
Arora A, Jalali RK, Vohora D. Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs. Ther Clin Risk Manag 2017;13:1195-203. DOI: https://doi.org/10.2147/TCRM.S137144

How to Cite

Einollahi, B., Nafar, M., Javanbakht, M., Alirezaei, A., Azmandian, J., Etminan, A., Ardalan, M. R., Etemadi, J., Akbari, R., Pourfarziani, V., Hashemi, S. S. R., Rahbar, S. M., Shahidi, S., Safa, J., Khosroshahi, H. T., Azar, S. A., Ossareh, S., Atapour, A., Marghoob, B., Nazemian, F., Kafi, H., & Sabzvari, A. (2025). Evaluation of efficacy and safety of generic tacrolimus (Suprotac®) compared to reference tacrolimus (Prograf<sup>®</sup>) in kidney transplantation: a phase IV study. European Journal of Translational Myology. https://doi.org/10.4081/ejtm.2025.13203